If validated in larger, independent studies, SP17 antibodies might be useful in the diagnosis and/or prognosis of HNSCC, alone or in combination with recently discovered serological biomarkers of the disease, namely IFN-γ, IL-13, and MIP-1β [19]. This evidence concerns the gene IL13 and head and neck squamous cell carcinoma.